"Total worldwide revenue was $73 million, representing growth of approximately 9% year-over-year." - Jim Clemmer, CEO
— Jim Clemmer
03Detailed Report
ANGO
AngioDynamics Inc
Period
Q2 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 27, 2026
Swipe to view all report sections
Executive Summary
AngioDynamics Inc (ANGO) reported its fiscal Q2 2025 results with total revenue of $73 million, marking a 9.2% growth year-over-year, primarily driven by strong performance within its MedTech segment, which saw a 25% increase in revenue. Despite posting a net income loss of $10.7 million for the quarter, management has expressed optimism regarding the company’s trajectory towards profitability with positive adjusted EBITDA of $3.1 million and expectations of sustained profitability moving forward. Improved performance metrics reinforce the company’s strategic pivot towards high-growth MedTech markets, whereby adjusted EBITDA is projected to be positive for the full year, showcasing effective cost management and revenue growth strategies.
Key Performance Indicators
Revenue
Decreasing
72.85M
QoQ: 7.93% | YoY: -7.88%
Gross Profit
Decreasing
39.91M
54.78% margin
QoQ: 8.66% | YoY: -0.88%
Operating Income
Increasing
-2.51M
QoQ: 80.85% | YoY: 80.88%
Net Income
Increasing
-10.74M
QoQ: 16.10% | YoY: 63.03%
EPS
Increasing
-0.26
QoQ: 16.13% | YoY: 63.89%
Revenue Trend
Margin Analysis
Financial Highlights
##### Key Financial Metrics:
- Total Revenue: $73 million (YoY +9.2%)
- Gross Profit: $39.9 million (YoY -0.9%)
- Operating Income: -$2.5 million (YoY Improve +80.8%)
- Net Income: -$10.7 million (YoY Improve +63.0% from losses)
- Adjusted EBITDA: $3.1 million
- Cash Position: $54.1 million at period end
Overall, the revenue performance depicts a solid momentum in recovery primarily attributed to the MedTech segment's diversification and market expansion initiatives.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
72.85M
-7.88%
7.93%
Gross Profit
39.91M
-0.88%
8.66%
Operating Income
-2.51M
80.88%
80.85%
Net Income
-10.74M
63.03%
16.10%
EPS
-0.26
63.89%
16.13%
Key Financial Ratios
Gross Profit Margin
Good
54.80%
Gross profit margin is healthy and competitive within industry standards
Operating Profit Margin
Weak
-0.03%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-0.15%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.04%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.06%
Return on equity suggests inefficient capital allocation
Current Ratio
Healthy
1.98
Current ratio shows adequate liquidity to meet short-term obligations
Debt to Equity
Conservative
0.03
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-6.60x
Negative earnings make P/E ratio not meaningful
Price to Book
Fair Value
1.52x
Price-to-book ratio reasonable for profitable companies
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.